Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project

[1]  F. Di Lorenzo,et al.  Iron and aluminum in Alzheimer's disease. , 2013, Neuro endocrinology letters.

[2]  J. Connor,et al.  Expression of the HFE allelic variant H63D in SH-SY5Y cells affects tau phosphorylation at serine residues , 2011, Neurobiology of Aging.

[3]  J. Connor,et al.  HFE polymorphisms affect cellular glutamate regulation , 2011, Neurobiology of Aging.

[4]  J. Connor,et al.  Prolyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with the expression of the HFE polymorphic allele, H63D. , 2010, Biochimica et biophysica acta.

[5]  K. Franz,et al.  Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease. , 2010, Dalton transactions.

[6]  Isidro Ferrer,et al.  Mitochondrial ATP‐Synthase in the Entorhinal Cortex Is a Target of Oxidative Stress at Stages I/II of Alzheimer's Disease Pathology , 2010, Brain pathology.

[7]  M. Owen,et al.  Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[8]  Jim Mintz,et al.  Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. , 2010, Journal of Alzheimer's disease : JAD.

[9]  George Perry,et al.  Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.

[10]  Wei Wang,et al.  Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. , 2009, Radiology.

[11]  D. Jiang,et al.  Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. , 2009, Biochemistry.

[12]  Mario Cortina-Borja,et al.  Open Access Journal of Neuroinflammation Replication by the Epistasis Project of the Interaction between the Genes for Il-6 and Il-10 in the Risk of Alzheimer's Disease , 2022 .

[13]  M. Kivipelto,et al.  Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later , 2009, Dementia and Geriatric Cognitive Disorders.

[14]  G. Perry,et al.  Getting the iron out: phlebotomy for Alzheimer's disease? , 2009, Medical hypotheses.

[15]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[16]  M. Fornage,et al.  Genomewide association studies of stroke. , 2009, The New England journal of medicine.

[17]  Hua-wei Ling,et al.  Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease , 2009, Journal of magnetic resonance imaging : JMRI.

[18]  A. Hofman,et al.  HFE variants, APOE and Alzheimer's disease: Findings from the population-based Rotterdam Study , 2009, Neurobiology of Aging.

[19]  M. Muckenthaler,et al.  Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. , 2009, Journal of Alzheimer's disease : JAD.

[20]  Mario Cortina-Borja,et al.  The synergy factor: a statistic to measure interactions in complex diseases , 2009, BMC Research Notes.

[21]  D. Blacker,et al.  Assessment of Alzheimer’s disease case–control associations using family-based methods , 2009, neurogenetics.

[22]  A. Fagan,et al.  Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.

[23]  Z. Rahimi,et al.  Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. , 2008, Clinical biochemistry.

[24]  D. Sparks,et al.  Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity , 2008, Glia.

[25]  K. Nakashima,et al.  Sugar Chains of Cerebrospinal Fluid Transferrin as a New Biological Marker of Alzheimer’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.

[26]  W. Streit,et al.  Microglial degeneration in the aging brain--bad news for neurons? , 2008, Frontiers in bioscience : a journal and virtual library.

[27]  S. Mandel,et al.  Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  R. Maccioni,et al.  Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. , 2008, Journal of Alzheimer's disease : JAD.

[29]  Jim Mintz,et al.  Brain ferritin iron may influence age- and gender-related risks of neurodegeneration , 2007, Neurobiology of Aging.

[30]  J. Keller,et al.  Oxidative inactivation of the proteasome in Alzheimer's disease , 2007, Free radical research.

[31]  D. Butterfield,et al.  The expression of key oxidative stress-handling genes in different brain regions in alzheimer’s disease , 1998, Journal of Molecular Neuroscience.

[32]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[33]  Cecilia Hidalgo,et al.  Calcium, iron and neuronal function , 2007, IUBMB life.

[34]  M Worwood,et al.  Iron genes, iron load and risk of Alzheimer’s disease , 2006, Journal of Medical Genetics.

[35]  Daniela Berg,et al.  Iron metabolism in Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[36]  W. Markesbery,et al.  Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease , 2006, Neurobiology of Aging.

[37]  D. Dickson,et al.  Induction of vascular amyloidosis-β by oxidative stress depends on APOE genotype , 2006, Neurobiology of Aging.

[38]  D. Allan Butterfield,et al.  Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease , 2006, Neurobiology of Disease.

[39]  W. Markesbery,et al.  Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment , 2006, Journal of neurochemistry.

[40]  Reeti Tandon,et al.  High-field Magnetic Resonance Imaging of Brain Iron in Alzheimer Disease , 2006, Topics in magnetic resonance imaging : TMRI.

[41]  D. Dickson,et al.  Induction of vascular amyloidosis-beta by oxidative stress depends on APOE genotype. , 2006, Neurobiology of aging.

[42]  J. Morrow,et al.  Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.

[43]  W. Markesbery,et al.  Ribosome Dysfunction Is an Early Event in Alzheimer's Disease , 2005, The Journal of Neuroscience.

[44]  L. Messori,et al.  The C2 variant of human serum transferrin retains the iron binding properties of the native protein. , 2005, Biochimica et biophysica acta.

[45]  K. Sleegers,et al.  Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. , 2005, American journal of epidemiology.

[46]  F. Panza,et al.  The cathepsin D gene exon 2 (C224T) polymorphism and sporadic Alzheimer's disease in European populations. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[47]  Xiongwei Zhu,et al.  Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron* , 2005, Journal of Biological Chemistry.

[48]  F. Schmitt,et al.  Evidence of increased oxidative damage in subjects with mild cognitive impairment , 2005, Neurology.

[49]  E. Corder,et al.  Transferrin neutralization of amyloid β 25-35 cytotoxicity , 2004 .

[50]  A. Hofman,et al.  Does bilirubin protect against hemochromatosis gene (HFE) related mortality? , 2004, American journal of medical genetics. Part A.

[51]  Paige S. Davies,et al.  Expression of the Hereditary Hemochromatosis Protein HFE Increases Ferritin Levels by Inhibiting Iron Export in HT29 Cells* , 2004, Journal of Biological Chemistry.

[52]  F. Potocnik,et al.  5- and 6-Glycosylation of Transferrin in Patients with Alzheimer's Disease , 2004, Metabolic Brain Disease.

[53]  A. Smith,et al.  Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease , 2004, Journal of Medical Genetics.

[54]  H. G. van Eijk,et al.  Influence of transferrin glycans on receptor binding and iron-donation , 1997, Glycoconjugate Journal.

[55]  H. G. Eijk,et al.  Transferrin microheterogeneity in rheumatoid arthritis , 1992, Rheumatology International.

[56]  E. Corder,et al.  Transferrin neutralization of amyloid beta 25-35 cytotoxicity. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[57]  H. Cleve,et al.  Genetic transferrin types and iron-binding: a comparative study of a European and an African population sample , 2004, Human Genetics.

[58]  H. Chertkow,et al.  Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma , 2003, Proteomics.

[59]  Paige S. Davies,et al.  Mechanisms of HFE-induced regulation of iron homeostasis: Insights from the W81A HFE mutation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  E. Yavin,et al.  Pro‐apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity , 2003, Journal of neurochemistry.

[61]  O. Combarros,et al.  Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[62]  廣瀬 渉.  Age-associated increases in heme oxygenase-1 and ferritin immunoreactivity in the autopsied brain , 2003 .

[63]  Xudong Huang,et al.  An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.

[64]  A. Townsend,et al.  The hemochromatosis protein HFE inhibits iron export from macrophages , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Pouchard,et al.  Gender‐specific phenotypic expression and screening strategies in C282Y‐linked haemochromatosis: a study of 9396 French people , 2002, British journal of haematology.

[66]  J. Trojanowski,et al.  Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.

[67]  D. Small,et al.  Wheat germ agglutinin‐binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid , 2001, Journal of neurochemistry.

[68]  M. Worwood,et al.  HFE mutations, iron deficiency and overload in 10 500 blood donors , 2001, British journal of haematology.

[69]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[70]  G. Annoni,et al.  The hemochromatosis gene affects the age of onset of sporadic Alzheimer’s disease , 2001, Neurobiology of Aging.

[71]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[72]  Ashley I. Bush,et al.  Redox-active iron mediates amyloid-β toxicity , 2001 .

[73]  M. Smith,et al.  Redox-active iron mediates amyloid-beta toxicity. , 2001, Free radical biology & medicine.

[74]  M. Colombo,et al.  Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. , 2000, Blood.

[75]  S. Tsuji,et al.  Apolipoprotein E allele–dependent antioxidant activity in brains with Alzheimer’s disease , 2000, Neurology.

[76]  J. Connor,et al.  Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. , 2000, Cellular and molecular biology.

[77]  Y. Christen,et al.  Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain , 2000, Neurobiology of Disease.

[78]  Mark A. Smith,et al.  In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease , 2000, Journal of neurochemistry.

[79]  Jennifer J. Pointon,et al.  Geography of HFE C282Y and H63D mutations. , 2000, Genetic testing.

[80]  G. Bartzokis,et al.  In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. , 2000, Archives of general psychiatry.

[81]  Y. Christen,et al.  Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. , 1999, Free radical biology & medicine.

[82]  W R Markesbery,et al.  The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. , 1999, The American journal of pathology.

[83]  M. Smith,et al.  Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? , 1999, Free radical biology & medicine.

[84]  J. Trojanowski,et al.  Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  W. D. Ehmann,et al.  Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. , 1998, Neurotoxicology.

[86]  F. Ye,et al.  Increasing striatal iron content associated with normal aging , 1998, Movement disorders : official journal of the Movement Disorder Society.

[87]  D. M. Penny,et al.  The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[88]  L. Beckman,et al.  Transferrin C2, metal binding and Alzheimer's disease , 1998, Neuroreport.

[89]  R. Wolff,et al.  The Hemochromatosis Founder Mutation in HLA-H Disrupts β2-Microglobulin Interaction and Cell Surface Expression* , 1997, The Journal of Biological Chemistry.

[90]  P. Lewitt,et al.  Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders , 1996, Brain Research.

[91]  W. D. Ehmann,et al.  Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress , 1996, Journal of the Neurological Sciences.

[92]  Jonathan D. Smith,et al.  Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.

[93]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[94]  D. Schubert,et al.  The role of iron in beta amyloid toxicity. , 1995, Biochemical and biophysical research communications.

[95]  J. Connor,et al.  Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.

[96]  J. Connor,et al.  A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.

[97]  W. Klein,et al.  Iron Levels Modulate α‐Secretase Cleavage of Amyloid Precursor Protein , 1995, Journal of neurochemistry.

[98]  Jim Mintz,et al.  In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI , 1994, Biological Psychiatry.

[99]  C. Morris,et al.  Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus. , 1994, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[100]  J. Taljaard,et al.  Increased frequency of the transferrin C2 subtype in Alzheimer's disease. , 1993, Neuroreport.

[101]  J. Connor,et al.  Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease , 1993, Neuroscience Letters.

[102]  P. Mantyh,et al.  Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.

[103]  G. Hallmans,et al.  Transferrin types, iron-binding capacity and body iron stores. , 1993, Human heredity.

[104]  K. Savage,et al.  Expression of glycosylated and nonglycosylated human transferrin in mammalian cells. Characterization of the recombinant proteins with comparison to three commercially available transferrins. , 1993, Biochemistry.

[105]  D. Walker,et al.  Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. , 1993, The American journal of pathology.

[106]  D. Perl,et al.  Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study , 1992, Annals of neurology.

[107]  J. Connor,et al.  Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.

[108]  J. Connor,et al.  A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.

[109]  S W Atlas,et al.  Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5 T. , 1991, Radiology.

[110]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[111]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[112]  C. Wong,et al.  Effects of transferrin genetic phenotypes on total iron-binding capacity. , 1986, Acta haematologica.

[113]  G. Beckman,et al.  Transferrin C2 as an enhancer of cyto- and genotoxic damage. , 1986, Progress in clinical and biological research.

[114]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[115]  L. Goodman.  Alzheimer's disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. , 1953, The Journal of nervous and mental disease.